Sharam Danesh, MD
Ophthalmology · Phoenix, AZNPI 1003808809
Payments from drug & device makers
Across 109 payments — averaging $203.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma Global Development$8K
- Novartis$5K
- Boehringer Ingelheim International GmbH$3K
- Eyepoint US, Inc.$2K
- Genentech USA, Inc.$678
- Notal Vision, Inc.$519
- plus $3K from 18 others
Across 2 payments — averaging $49.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$100
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma Global Development | 1 | $7,793 |
| Novartis | 4 | $5,282 |
| Boehringer Ingelheim International GmbH | 26 | $2,840 |
| Eyepoint US, Inc. | 5 | $1,894 |
| Genentech USA, Inc. | 18 | $678 |
| Notal Vision, Inc. | 1 | $519 |
| AbbVie(2 entities) | 12 | $396 |
| Boehringer Ingelheim | 2 | $389 |
| Regeneron Healthcare Solutions, Inc. | 9 | $361 |
| Dutch Ophthalmic, USA | 3 | $318 |
| Alcon | 5 | $282 |
| Apellis Pharmaceuticals, Inc. | 4 | $244 |
| Astellas Pharma US Inc | 4 | $205 |
| Eyevance Pharmaceuticals LLC | 1 | $171 |
| Glaukos Corporation | 1 | $132 |
| Kala Pharmaceuticals, Inc. | 1 | $122 |
| F. Hoffmann-la Roche AG | 1 | $112 |
| Genentech, Inc. | 1 | $102 |
| Carl Zeiss Meditec USA, Inc. | 2 | $93 |
| Coherus Oncology, Inc. | 3 | $80 |
| Heidelberg Engineering, Inc. | 1 | $68 |
| Bausch & Lomb Americas Inc. | 2 | $35 |
| LKC Technologies, Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
How this compares
$22,154 in reported general payments places this provider in the 85th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Phoenix
- Ramin SchadluPhoenix$1.8M
- John CasonPhoenix$1.7M
- Benjamin HellerPhoenix$1.1M
- Neal PalejwalaPhoenix$627K
- Pravin DugelPhoenix$479K
- Robert GrossPhoenix$268K
- Sujit IttyPhoenix$216K
- Jung DaoPhoenix$213K
- Karim JamalPhoenix$101K
- Nishi ShahPhoenix$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.